よむ、つかう、まなぶ。
04資料2-1_森野委員提出資料（おたふくかぜワクチンファクトシート第２版） (45 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_73851.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第34回 6／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
ORIX.PDF (accessed 2026/04/24).
90.
Group M-S. A second dose of a measles-mumps-rubella vaccine administered to healthy four-
to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study
comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines coadministration. Hum Vaccin Immunother 2019; 15(4): 786–99.
91.
Abu-Elyazeed R, Jennings W, Severance R, et al. Immunogenicity and safety of a second dose
of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A
phase III, randomized study. Hum Vaccin Immunother 2018; 14(11): 2624–31.
92.
Klein NP, Abu-Elyazeed R, Povey M, et al. Immunogenicity and Safety of a Measles-Mumps-
Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III,
Randomized, Noninferiority, Lot-to-Lot Consistency Study. Journal of the Pediatric Infectious Diseases
Society 2019; 9(2): 194–201.
93.
MMR-161StudyGroup. Immunogenicity and safety of measles-mumps-rubella vaccine at two
different potency levels administered to healthy children aged 12-1 months: A phase III, randomized,
non-inferiority trial. Vaccine 2018; 36(38): 5781–8.
94.
MMR-162StudyGroup. Safety and immunogenicity of an upper-range release titer measles-
mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study.
Hum Vaccin Immunother 2018; 14(12): 2921–31.
95.
Nakayama T, Eda M, Hirano M, Goto W. Immunogenicity and safety of the new MMR
vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese
children: a randomized phase I/II clinical trial. Hum Vaccin Immunother 2019; 15(5): 1139–44.
96.
Nakayama T, Kawamura A, Sogawa Y, et al. Phase III, open-label, single-arm study of a new
45
90.
Group M-S. A second dose of a measles-mumps-rubella vaccine administered to healthy four-
to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study
comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines coadministration. Hum Vaccin Immunother 2019; 15(4): 786–99.
91.
Abu-Elyazeed R, Jennings W, Severance R, et al. Immunogenicity and safety of a second dose
of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A
phase III, randomized study. Hum Vaccin Immunother 2018; 14(11): 2624–31.
92.
Klein NP, Abu-Elyazeed R, Povey M, et al. Immunogenicity and Safety of a Measles-Mumps-
Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III,
Randomized, Noninferiority, Lot-to-Lot Consistency Study. Journal of the Pediatric Infectious Diseases
Society 2019; 9(2): 194–201.
93.
MMR-161StudyGroup. Immunogenicity and safety of measles-mumps-rubella vaccine at two
different potency levels administered to healthy children aged 12-1 months: A phase III, randomized,
non-inferiority trial. Vaccine 2018; 36(38): 5781–8.
94.
MMR-162StudyGroup. Safety and immunogenicity of an upper-range release titer measles-
mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study.
Hum Vaccin Immunother 2018; 14(12): 2921–31.
95.
Nakayama T, Eda M, Hirano M, Goto W. Immunogenicity and safety of the new MMR
vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese
children: a randomized phase I/II clinical trial. Hum Vaccin Immunother 2019; 15(5): 1139–44.
96.
Nakayama T, Kawamura A, Sogawa Y, et al. Phase III, open-label, single-arm study of a new
45